Back to Search Results

Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approach.

Department of Biotechnology, Science Campus, Alagappa University, Karaikudi 630 003, India; Department of Systems Biology, Science Research Centre, Yonsei University, Seoul 03722, South Korea. Department of Biotechnology, Science Campus, Alagappa University, Karaikudi 630 003, India. Department of Biotechnology, Science Campus, Alagappa University, Karaikudi 630 003, India. Electronic address: mrbiotech.alu@gmail.com. Department of Life Sciences, National University of Kaohsiung, Kaohsiung 811, Taiwan.

Genomics. 2020;(6):4486-4504
Full text from:

Other resources

Abstract

Understanding the immunological behavior of COVID-19 cases at molecular level is essential for therapeutic development. In this study, multi-omics and systems pharmacology analyses were performed to unravel the multi-targeted mechanisms of novel bioactives to combat COVID-19. Immuno-transcriptomic dataset of healthy controls and COVID-19 cases was retrieved from ArrayExpress. Phytocompounds from ethnobotanical plants were collected from PubChem. Differentially expressed 98 immune genes associated with COVID-19 were derived through NetworkAnalyst 3.0. Among 259 plant derived compounds, 154 compounds were targeting 13 COVID-19 immune genes involved in diverse signaling pathways. In addition, pharmacological properties of these phytocompounds were compared with COVID-19 drugs prescribed by WHO, and 25 novel phytocompounds were found to be more efficient with higher bioactive scores. The current study unravels the virogenomic signatures which can serve as therapeutic targets and identified phytocompounds with anti-COVID-19 efficacy. However, further experimental validation is essential to bring out these molecules as commercial drug candidates.